In this therapeutic scenario, and considering that EGFR pathway activation might hypothetically contribute to cancer progression even in tumors with no EGFR activating mutations (17), to investigate if a more potent pan-HER inhibition with dacomitinib would add any clinical benefit seemed a rational approach, either from a biological or a clinical perspective. The gene discussed is EGFR; the disease is cancer.